Coste del asma en pediatría en Españaun modelo de evaluación de costes basado en la prevalencia

  1. Blasco, Juan Antonio
  2. González Pérez-Yarza, Eduardo
  3. Lázaro de Mercado, Pablo
  4. Bonillo Perales, Antonio
  5. Díaz Vázquez, Carlos A.
  6. Moreno Galdó, Antonio
Revista:
Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )

ISSN: 1695-4033 1696-4608

Año de publicación: 2011

Volumen: 74

Número: 3

Páginas: 145-153

Tipo: Artículo

DOI: 10.1016/J.ANPEDI.2010.10.006 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Anales de Pediatría: Publicación Oficial de la Asociación Española de Pediatría ( AEP )

Resumen

Introduction Asthma is the most common chronic disease in childhood, reduces the quality of life of children and their families, and produces high social and health care costs. In Spain, the cost of managing paediatric asthma is unknown. Objective To estimate the cost of managing paediatric asthma in Spain and to examine its variability depending on asthma severity. Patients and methods The cost of asthma in children under 16 years in 2008 was estimated by building a costs assessment model including the factors that influence the cost of asthma in children: prevalence, distribution of disease severity, age, frequency of resources use depending on severity, and the cost of each resource. A sensitivity analysis was conducted to evaluate the underlying uncertainty depending on the variability of the estimators of resource use, the unit cost of each resource, and the prevalence. Results According to the model, the total cost of paediatric asthma in Spain is around 532 million euros, with a range of 392 to 693 million euros. Direct costs (health care costs) represent 60% of the total costs, and indirect costs (carer time), 40%. The mean annual cost per child with asthma is 1,149 euros, ranging from 403 euros for the mildest category of the disease to 5,380 euros for the most severe. Conclusions The cost of paediatric asthma in Spain is very high and depends on disease severity. Although the most important costs are for the health care system, indirect costs are not negligible.